Financial News
All News about Exelixis Inc
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://mms.businesswire.com/media/20230501005641/en/1679909/5/Exelixis_Logo_RGB_2023.jpg)
![](https://mms.businesswire.com/media/20230425006047/en/1679909/5/Exelixis_Logo_RGB_2023.jpg)
![](/next-assets/images/schema-image-default.png)
What 9 Analyst Ratings Have To Say About Exelixis
April 12, 2023
Via Benzinga
![](https://g.foolcdn.com/editorial/images/725323/medical-professional-holding-dollar-sign-paperweight.jpg)
![](/next-assets/images/schema-image-default.png)
Analyst Ratings for Exelixis
March 20, 2023
Via Benzinga
![](https://g.foolcdn.com/editorial/images/723587/physician-giving-medicine-to-elderly-patient.jpg)
![](https://g.foolcdn.com/editorial/images/728539/stack-of-coins-and-a-piggy-bank.jpeg)
![](https://g.foolcdn.com/editorial/images/728582/bear-market-stocks-plunge-crash-invest-correction-getty.jpg)
![](https://mms.businesswire.com/media/20230413005756/en/1679909/5/Exelixis_Logo_RGB_2023.jpg)
![](https://mms.businesswire.com/media/20230405005800/en/1679909/5/Exelixis_Logo_RGB_2023.jpg)
Exelixis Reiterates Commitment to Shareholder Value Creation
April 05, 2023
From Exelixis, Inc.
Via Business Wire
![](/next-assets/images/schema-image-default.png)
The Latest Analyst Ratings for Exelixis
March 03, 2023
Via Benzinga
![](https://g.foolcdn.com/editorial/images/726994/two-people-in-a-lab.jpeg)
![](https://cdn.benzinga.com/files/images/story/2023/04/05/mark_avatar.png?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/04/05/exel.png?width=1200&height=800&fit=crop)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://g.foolcdn.com/editorial/images/726600/doctor-smiling-and-holding-patients-hand.jpg)
![](https://www.investors.com/wp-content/uploads/2017/05/IRU1.jpg)
![](https://mms.businesswire.com/media/20230320005238/en/1679909/5/Exelixis_Logo_RGB_2023.jpg)
Exelixis Announces $550 Million Share Repurchase Program
March 20, 2023
From Exelixis, Inc.
Via Business Wire
![](https://g.foolcdn.com/editorial/images/724894/scientists-in-a-lab-smiling.jpg)
![](https://www.investors.com/wp-content/uploads/2017/05/IRU1.jpg)
![](https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600.png)
![](https://mms.businesswire.com/media/20230313005670/en/1679909/5/Exelixis_Logo_RGB_2023.jpg)
![](https://g.foolcdn.com/editorial/images/723651/bear-market-stocks-plunge-crash-invest-correction-getty.jpg)
![](/next-assets/images/schema-image-default.png)
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/03/03/exel_co_cabometyx_20mg.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/03/03/share_market_photo_by_ashdesign_on_shutterstock.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/03/03/image-dell_technologies.png?width=1200&height=800&fit=crop)
![](https://mms.businesswire.com/media/20230302005857/en/1728975/22/Exelixis_Logo_RGB_2023.jpg)
![](https://mms.businesswire.com/media/20230228006371/en/1679909/5/Exelixis_Logo_RGB_2023.jpg)
From Exelixis, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.